S. 3633 · 110th Congress

Transparency in Drug Labeling Act

Stage
In committee
Introduced
2008-09-26
Latest action
2008-09-26 · Introduced in Senate

Summary

Transparency in Drug Labeling Act - Amends the Federal Food, Drug, and Cosmetic Act to deem a drug to be misbranded unless the labeling of such drug lists the identity of the country of manufacture of each active ingredient and each inactive ingredient of the drug, listed in descending order based on the percentage of the number of such ingredients in the final dosage form manufactured in such countries.